Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group
Publication in refereed journal
已正式接受出版

香港中文大學研究人員

引用次數
替代計量分析
.

其它資訊
摘要Objective
Adaptive trial design was developed initially for oncology to improve trial efficiency. If optimized for rheumatology, it may improve trial efficiency by reducing sample size and time.

Methods
A systematic review assessed design of phase II clinical trials in rheumatoid arthritis.

Results
Fifty-six trials were reviewed. Most trials had 4 groups (1 control and 3 intervention), with an average group size of 34 patients. American College of Rheumatology 20 measured at 16 weeks was the most commonly used primary endpoint.

Conclusion
The next step is to undertake a systematic review of adaptive designs used in early-phase trials in nonrheumatic conditions.
出版社接受日期18.12.2018
著者Tim Pickles, Rieke Alten, Maarten Boers, Vivian Bykerk, Jared Christensen, Robin Christensen, Hubert van Hoogstraten, Lee S. Simon, Lai-Shan Tam and Ernest H. Choy
期刊名稱Journal of Rheumatology
出版年份2019
國際標準期刊號0315-162X
電子國際標準期刊號1499-2752
語言英式英語
關鍵詞ADAPTIVE TRIAL DESIGN, OMERACT CORE OUTCOME SET, EARLY-PHASE CLINICAL TRIAL, RHEUMATOID ARTHRITIS, SYSTEMATIC REVIEW

上次更新時間 2021-28-09 於 01:08